FLX475 in Combination With Ipilimumab in Advanced Melanoma

Status Terminated

Clinical Trial Summary

This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-programmed cell death 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agent. The study will be conducted starting with a safety run-in portion in which 6 eligible subjects will be enrolled and treated for at least one 3-week cycle to determine if the safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately 20-subject study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04894994
Study type	Interventional
Source	RAPT Therapeutics, Inc.
Contact
Status	Terminated
Phase	Phase 2
Start date	September 3, 2021
Completion date	September 13, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05039801` - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	Phase 1
Completed	`NCT01621490` - PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma	Phase 1
Recruiting	`NCT05098184` - Study on TIL for the Treatment of Advanced Melanoma	Early Phase 1
Completed	`NCT02177110` - A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Completed	`NCT00197912` - Dendritic Cell Based Therapy of Malignant Melanoma	Phase 1/Phase 2
Completed	`NCT04165967` - Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma	Phase 1
Active, not recruiting	`NCT04495257` - A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)	Phase 1
Recruiting	`NCT05968690` - Naltrexone and Propranolol Combined With Immunotherapy	Phase 1
Active, not recruiting	`NCT03200847` - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma	Phase 1/Phase 2
Recruiting	`NCT05105100` - Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
Completed	`NCT02171286` - The Oncopanel Pilot (TOP) Study	N/A
Terminated	`NCT01453361` - Phase II FANG™ in Advanced Melanoma	Phase 2
Recruiting	`NCT05120024` - Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Active, not recruiting	`NCT04951583` - Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma	Phase 2
Recruiting	`NCT06112808` - A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin	Phase 1
Recruiting	`NCT01614301` - Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma	Phase 1/Phase 2
Recruiting	`NCT04640545` - A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma	Phase 1
Active, not recruiting	`NCT03086174` - Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma	Phase 1
Recruiting	`NCT03917069` - Nab-PCE vs PC for MM After Failure of Anti-PD-1	Phase 2